vs
Side-by-side financial comparison of COMERICA INC (CMA) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
COMERICA INC is the larger business by last-quarter revenue ($838.0M vs $622.0M, roughly 1.3× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 21.0%, a 13.4% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 3.3%). Over the past eight quarters, COMERICA INC's revenue compounded faster (108.9% CAGR vs 4.6%).
Comerica Incorporated is an American financial services company, headquartered in Dallas, Texas. It is the parent of Comerica Bank, a regional commercial bank with 413 branches in the U.S. states of Texas, Michigan, California, Florida and Arizona. Comerica is among the largest U.S. financial holding companies, with offices in a number of U.S. cities.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
CMA vs RPRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $838.0M | $622.0M |
| Net Profit | $176.0M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | — | 62.4% |
| Net Margin | 21.0% | 34.4% |
| Revenue YoY | 3.3% | 4.8% |
| Net Profit YoY | -4.3% | 2.9% |
| EPS (diluted) | $1.35 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $622.0M | ||
| Q3 25 | $838.0M | $609.3M | ||
| Q2 25 | $849.0M | $578.7M | ||
| Q1 25 | $829.0M | $568.2M | ||
| Q4 24 | $825.0M | $593.6M | ||
| Q3 24 | $811.0M | $564.7M | ||
| Q2 24 | $824.0M | $537.3M | ||
| Q1 24 | $784.0M | $568.0M |
| Q4 25 | — | $214.2M | ||
| Q3 25 | $176.0M | $288.2M | ||
| Q2 25 | $199.0M | $30.2M | ||
| Q1 25 | $172.0M | $238.3M | ||
| Q4 24 | $170.0M | $208.2M | ||
| Q3 24 | $184.0M | $544.0M | ||
| Q2 24 | $206.0M | $102.0M | ||
| Q1 24 | $138.0M | $4.8M |
| Q4 25 | — | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | — | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 50.2% | ||
| Q1 24 | — | -13.0% |
| Q4 25 | — | 34.4% | ||
| Q3 25 | 21.0% | 47.3% | ||
| Q2 25 | 23.4% | 5.2% | ||
| Q1 25 | 20.7% | 41.9% | ||
| Q4 24 | 20.6% | 35.1% | ||
| Q3 24 | 22.7% | 96.3% | ||
| Q2 24 | 25.0% | 19.0% | ||
| Q1 24 | 17.6% | 0.8% |
| Q4 25 | — | $0.49 | ||
| Q3 25 | $1.35 | $0.67 | ||
| Q2 25 | $1.42 | $0.07 | ||
| Q1 25 | $1.25 | $0.55 | ||
| Q4 24 | $1.22 | $0.46 | ||
| Q3 24 | $1.33 | $1.21 | ||
| Q2 24 | $1.49 | $0.23 | ||
| Q1 24 | $0.98 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $618.7M |
| Total DebtLower is stronger | $5.4B | $9.0B |
| Stockholders' EquityBook value | $7.4B | $9.7B |
| Total Assets | $77.4B | $19.6B |
| Debt / EquityLower = less leverage | 0.73× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
| Q4 25 | — | $9.0B | ||
| Q3 25 | $5.4B | $8.9B | ||
| Q2 25 | $5.8B | $8.0B | ||
| Q1 25 | $5.7B | $7.6B | ||
| Q4 24 | $6.7B | $7.6B | ||
| Q3 24 | $6.8B | $7.6B | ||
| Q2 24 | $7.1B | $7.6B | ||
| Q1 24 | $7.1B | $6.1B |
| Q4 25 | — | $9.7B | ||
| Q3 25 | $7.4B | $9.6B | ||
| Q2 25 | $6.9B | $9.5B | ||
| Q1 25 | $7.1B | $9.8B | ||
| Q4 24 | $6.5B | $10.3B | ||
| Q3 24 | $7.4B | $10.3B | ||
| Q2 24 | $6.2B | $9.8B | ||
| Q1 24 | $6.0B | $9.9B |
| Q4 25 | — | $19.6B | ||
| Q3 25 | $77.4B | $19.3B | ||
| Q2 25 | $78.0B | $18.3B | ||
| Q1 25 | $77.6B | $17.6B | ||
| Q4 24 | $79.3B | $18.2B | ||
| Q3 24 | $79.7B | $18.0B | ||
| Q2 24 | $79.6B | $17.7B | ||
| Q1 24 | $79.4B | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | 0.73× | 0.93× | ||
| Q2 25 | 0.84× | 0.84× | ||
| Q1 25 | 0.81× | 0.78× | ||
| Q4 24 | 1.02× | 0.74× | ||
| Q3 24 | 0.92× | 0.74× | ||
| Q2 24 | 1.15× | 0.78× | ||
| Q1 24 | 1.18× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-270.0M | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -1.53× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $827.1M | ||
| Q3 25 | $-270.0M | $702.6M | ||
| Q2 25 | $476.0M | $364.0M | ||
| Q1 25 | $273.0M | $596.1M | ||
| Q4 24 | $601.0M | $742.5M | ||
| Q3 24 | $1.0B | $703.6M | ||
| Q2 24 | $111.0M | $658.2M | ||
| Q1 24 | $-205.0M | $664.6M |
| Q4 25 | — | 3.86× | ||
| Q3 25 | -1.53× | 2.44× | ||
| Q2 25 | 2.39× | 12.06× | ||
| Q1 25 | 1.59× | 2.50× | ||
| Q4 24 | 3.54× | 3.57× | ||
| Q3 24 | 5.70× | 1.29× | ||
| Q2 24 | 0.54× | 6.45× | ||
| Q1 24 | -1.49× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMA
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
